Welcome to our dedicated page for LNG Energy Group news (Ticker: MCURF), a resource for investors and traders seeking the latest updates and insights on LNG Energy Group stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LNG Energy Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LNG Energy Group's position in the market.
Mind Cure Health Inc. (CSE: MCUR, OTCQX: MCURF) announced that its digital therapeutics technology, iSTRYM, has achieved HIPAA compliance. This milestone underscores the Company's commitment to medical data protection and paves the way for iSTRYM's classification as a Software as a Medical Device by the FDA. The Company aims to commercially deploy iSTRYM by the second quarter of 2022, which could facilitate revenue generation. Additionally, MINDCURE is expanding its partnerships with clinics and plans to extend iSTRYM to European markets by Q4 2022.
Mind Cure Health Inc. has appointed Dr. Doron Sagman as the new Chief Medical Officer, transitioning Dr. Joel Raskin to an advisory role. Dr. Sagman, with over 30 years in clinical, research, and regulatory experience, aims to advance MINDCURE’s mission of innovating mental health care and integrating psychedelic-assisted therapy. His extensive background includes leadership at Eli Lilly Canada. Dr. Sagman expressed excitement about contributing to addressing unmet mental health needs, while CEO Kelsey Ramsden highlighted his capability to lead innovative therapy development.
Mind Cure Health (CSE: MCUR, OTCQX: MCURF) will have President & CEO Kelsey Ramsden present at multiple conferences in December 2021, enhancing its visibility in the psychedelics sector. Key events include H.C. Wainwright's 2nd Annual Psychedelics Conference on December 6, the Psychedelics Now Virtual Conference on December 8, and the Life Sciences Investor Forum on December 16. Additionally, the company granted 10,000 stock options to employees at an exercise price of $0.29 per share.
Mind Cure Health provides an operational update, highlighting progress in their synthetic ibogaine production and clinical trials. The Company is on track to deliver Good Laboratory Practice (GLP) ibogaine by Q2 2022, with preliminary studies expected by Q1 2022. The Desire Project, targeting female sexual hypoactive desire disorder, is set to initiate Phase 2 trials by Q3 2022. The iSTRYM digital therapeutics platform has surpassed initial clinic partnerships, with plans for broader market expansion. MINDCURE aims to enhance its drug pipeline and solidify its position in the psychedelic-assisted therapy sector.
Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) has signed a non-binding letter of intent with Awakn Life Sciences to distribute ketamine-assisted psychotherapy for Alcohol Use Disorder through its iSTRYM digital platform in the US and Canada. Following the MVP launch in August, MINDCURE aims for full deployment across 75 partner clinics by Q1 2022, with expectations of expanding to 150 clinics by Q4 2022. This partnership adds a new revenue line for MINDCURE while advancing evidence-based treatment for addiction.
Mind Cure Health (CSE: MCUR, OTCQB: MCURF) has announced its participation in two significant events in November 2021. The company will be a Silver Sponsor at the Wonderland Miami conference on November 8-9, focusing on the psychedelic medicine industry, where CEO Kelsey Ramsden will engage in panel discussions. Additionally, MINDCURE will support the International Summit on Psychedelic Therapies hosted by Mind Medicine Australia on November 19-20, featuring a panel on the future of the psychedelic industry.
MINDCURE invites investors and analysts to a live presentation on October 13, 2021, at 12:00 PM ET via VirtualInvestorConferences.com. President & CEO Kelsey Ramsden will discuss the company's advancements in psychedelic research and digital therapeutics aimed at enhancing mental health. An archived webcast will be available for those unable to attend live. Pre-registration is recommended to improve participation. MINDCURE operates in the life sciences sector, focusing on evidence-based healing methods.
MINDCURE, a leader in psychedelic technology, has successfully graduated to the OTCQX Best Market from the OTCQB Venture Market, enhancing its visibility and accessibility for U.S. investors. This milestone, effective September 30, 2021, is expected to provide broader access to capital and attract a larger investor base. The transition validates MINDCURE's efforts in promoting mental health treatments through innovative technologies and clinical research. The move is anticipated to improve shareholder liquidity and support strategic growth initiatives.
Mind Cure Health Inc. (CSE: MCUR, OTCQB: MCURF) announced that its President & CEO, Kelsey Ramsden, will present at the Benzinga Healthcare Small Cap Conference on September 29, 2021, at 4:00 pm ET. Investors can register for the virtual event here. Ramsden will also hold one-on-one meetings with investors during the conference. Additionally, the company granted 10,000 stock options at $0.34 per share and issued 59,296 common shares to a consultant at $0.38 each.
Mind Cure Health Inc. (CSE: MCUR, OTCQB: MCURF) has announced its groundbreaking "Desire Project" aimed at treating female hypoactive sexual desire disorder (HSDD) through MDMA-assisted psychotherapy. HSDD affects an estimated 9.5 million women in the U.S., characterized by persistent low sexual desire and emotional distress. The clinical research program marks the first use of psychedelics for this condition, tapping into the untapped market. Led by prominent researchers, the project pursues innovative pathways for treatment, responding to the inadequacies of existing therapies.
FAQ
What is the market cap of LNG Energy Group (MCURF)?
